欢迎来到麦多课文档分享! | 帮助中心 海量文档,免费浏览,给你所需,享你所想!
麦多课文档分享
全部分类
  • 标准规范>
  • 教学课件>
  • 考试资料>
  • 办公文档>
  • 学术论文>
  • 行业资料>
  • 易语言源码>
  • ImageVerifierCode 换一换
    首页 麦多课文档分享 > 资源分类 > PPT文档下载
    分享到微信 分享到微博 分享到QQ空间

    BISPHOSPHONATE RELATEDOSTEONECROSIS OF THE .ppt

    • 资源ID:379013       资源大小:628.50KB        全文页数:33页
    • 资源格式: PPT        下载积分:2000积分
    快捷下载 游客一键下载
    账号登录下载
    微信登录下载
    二维码
    微信扫一扫登录
    下载资源需要2000积分(如需开发票,请勿充值!)
    邮箱/手机:
    温馨提示:
    如需开发票,请勿充值!快捷下载时,用户名和密码都是您填写的邮箱或者手机号,方便查询和重复下载(系统自动生成)。
    如需开发票,请勿充值!如填写123,账号就是123,密码也是123。
    支付方式: 支付宝扫码支付    微信扫码支付   
    验证码:   换一换

    加入VIP,交流精品资源
     
    账号:
    密码:
    验证码:   换一换
      忘记密码?
        
    友情提示
    2、PDF文件下载后,可能会被浏览器默认打开,此种情况可以点击浏览器菜单,保存网页到桌面,就可以正常下载了。
    3、本站不支持迅雷下载,请使用电脑自带的IE浏览器,或者360浏览器、谷歌浏览器下载即可。
    4、本站资源下载后的文档和图纸-无水印,预览文档经过压缩,下载后原文更清晰。
    5、试题试卷类文档,如果标题没有明确说明有答案则都视为没有答案,请知晓。

    BISPHOSPHONATE RELATEDOSTEONECROSIS OF THE .ppt

    1、BISPHOSPHONATE RELATED OSTEONECROSIS OF THE JAW (BRONJ),BISPHOSPHONATES AND WHAT HAPPENS TO BONE,VINCENT E. DIFABIO, DDS, MS MEMBER OF THE COMMITTEE ON HEALTHCARE AND ADVOCACY FROM THE AMERICAN ASSOCIATION OF ORAL & MAXILLOFACIAL SURGERY (AAOMS) ASSOCIATE PROFESSOR OF ORAL & MAXILLOFACIAL SURGERY UN

    2、IVERSITY OF MARYLAND, BALTIMORE, MARYLAND AND PRIVATE PRACTICE OF ORAL & MAXILLOFACIAL SURGERY, FREDERICK, MARYLAND,BISPHOSPHONATES AND WHAT HAPPENS TO BONE,PRESENT THE POTENTIAL FOR A DIFFERENT ETIOLOGY OF BONE DESTRUCTION IN THE MAXILLA AND MANDIBLE AND THE NEED FOR SPECIFIC CODES TO REPRESENT THI

    3、S DIFFERENT ETIOLOGY OF BONE DESTRUCTION SEEN IN THE MAXILLA AND MANDIBLE,OSTEONECROSIS OF THE JAW,NOT A NEW DISEASE OR PHENOMENON “PHOSSY JAW” DATES BACK TO THE 19TH CENTURY RELATED TO MATCHSTICK MAKING HIGH LEVELS OF PHOSPHORUS,BISPHOSPHONATES,ARE USED TO TREAT SEVERAL DISEASE ENTITIES OSTEOPOROSI

    4、S CANCER PATIENTS RECENT PAPERS HAVE SHOWN THAT A JAW OSTEONECROSIS OF ASEPTIC ETIOLOGY IS ASSOCIATED WITH THE USE OF BISPHOSPHONATES,OSTEOPOROSIS,TREATED WITH BISPHOSPHONATES (BPs) MANY PEOPLE WORLD WIDE ARE RECEIVING THESE TYPES OF MEDICATIONS IS THIS TREATMENT OF OSTEOPOROSIS WITH BPs OF CONCERN?

    5、,Osteoporosis,Primary disease: quantities of sex hormones Phase 1: trabecular bone resorption due to estrogen deficiency. Peaks after 4-8 years (women only) Phase 2: persistent, slower loss of both trabecular and cortical bone which is mainly due to decreased bone formation (men and women),Osteoporo

    6、sis,Secondary disease: consequence of other diseases or medications Long term steroid use, Cushings disease, anorexia nervosa, athletic amenorrhea, HPT, cystic fibrosis, inflammatory bowel disease, rheumatoid arthritisObserved in young/old, men/women Osteoporosis ICD-9-CM Codes: 733.0 733.09,Osteopo

    7、rosis,Unbalanced bone remodeling where bone formation = bone resorption Defined as a disease with low bone mass and deterioration of bone structure resulting in bone fragility and increase risk of fracture Females Males Primary vs. Secondary,Lerner AH, J. Dent Res 85. 2006,Osteoporosis is a BIG prob

    8、lem in the USA!,Surgeon General Report (2004) 40% of American women 50 yo. Will experience an osteoporotic fracture 13% of men 50 yo. By 2020 it is estimated that 50% of all Americans over the age of 50 will be at risk of developing osteoporosis Direct cost expenditures for 1.3 million fx per yr = $

    9、14 billion +,OSTEOPOROSIS,THE BIG QUESTION IS WILL THESE PATIENTS IN THE FUTURE DEVELOP A SIMILAR OSTEONECROSIS OF THE JAW?,OSTEORADIONECROSIS,NOTED WITH THE INTRODUCTION OF RADIATION THERAPY TO TUMORS OF THE HEAD AND NECK RADIATION CREATES HARD AND SOFT TISSUE HYPOXIA, HYPO-CELLULARITY AND HYPO-VAS

    10、CULARITY RESULTS IN A SIGNIFICANT DECREASE IN HEALING AND NECROSIS OF BONE OSTEORADIONECROSIS OF THE JAWS ICD - 9- CM CODE: 526.89,OSTEOMYELITIS,BACTERIAL INFECTION OF THE BONE PRIMARY OR SECONDARY TO DENTAL OR OTHER ORAL INFECTIONS OSTEOMYELITIS OF THE BONE: 730 730.9 INCLUDES ACUTE AND CHRONIC and

    11、 OSTEOMYELITIS OF THE JAW: 526.4 and 526.5,PATHOPHYSIOLOGY,ALTHOUGH THE OSTEORADIONECROSIS (RADIATION INDUCED), OSTEOMYELITIS (BACTERIAL INFECTION) AND BISPHOSPHONATE RELATED OSTEONECROSIS OF THE JAW (ASEPTIC NECROSIS & DRUG INDUCED) ARE DIFFERENT IN ETIOLOGY, THEY ARE SIMILAR IN PATHOLOGY AND SECON

    12、DARY INFECTIONS AND WILL THE OSTEOPOROSIS PATIENTS TREATED WITH BPs DEVELOP A SIMILAR ONJ IN THE FUTURE?,ICD-9-CM,WE HAVE SPECIFIC ICD-9-CM CODES FOR OSTEOPOROSIS, OSTEOMYELITIS AND OSTEORADIONECROSIS SO WHY NOT USE THESE CODES FOR BP RELATED ASEPTIC OSTEONECROSIS OF THE JAW OR BRON JAW?,NEED FOR A

    13、SPECIFIC CODE,REPORTING INCIDENCE OF OCCURRENCE AND TRACKING RESEARCH EVALUATION & MANAGEMENT AND SURGICAL PROCEDURES OF MAXILLA AND MANDIBLE LINKED TO A SPECIFIC VS NON-SPECIFIC ICD-9CM CODE,BISPHOSPHONATE RELATED OSTEONECROSIS OF THE JAW (ONJ),FIRST RECOGNIZED IN 2003 AS A COMPLICATION OF BISPHOSP

    14、HONATE THERAPY HIGHER FREQUENCY IN THE MANDIBLE (63%) THAN IN THE MAXILLA (38%) ETIOLOGY IS UNCLEAR AND IS THE SUBJECT OF CURRENT RESEARCH AND INVESTIGATION,BRONJ,CAN BE RELATED TO DENTAL TREATMENT CAN BE RELATED TO DENTAL PATHOLOGY CAN BE SPONTANEOUS WITH DENTAL ETIOLOGY CAN BE RELATED TO DENTURE I

    15、RRITATION OR WEAR CAN BE UNRELATED TO ANY OF THE ABOVE CAN BE RELATED TO LOCAL TRAUMA CAN BE UNKNOWN IN ETIOLOGY,PROPOSED INDUCTION MECHANISMS,INHIBITION OF OSTEOCLAST ACTIVITY REDUCES BONE TURNOVER REDUCING REMODELING DECREASED NEW BONE FORMATION ETIOLOGY IS UNKNOWN BUT IS LIKELY MULTIFACTORIAL,BRO

    16、NJ,TRUE INCIDENCE IS DIFFICULT TO ESTIMATE DEPENDING ON RECENT RETROSPECTIVE REPORTS COULD BE 1%-9% OF CANCER PATIENTS RECEIVING BISPHOSPHONATES SEEN IN CANCER PATIENTS WITH MULTIPLE ANTINEOPLASTIC MEDICATIONS AS WELL AS BISPHOSPHONATES MULTIPLE MYELOMA, BREAST CANCER AND PROSTATE CANCER ARE THE PRI

    17、MARY NEOPLASMS AFFECTED AND WHAT ABOUT OSTEOPOROSIS PATIENTS TREATED WITH BPs?,ONJ,MULTIPLE PAPERS RELATING BPs WITH ONJ SINCE 2003 RELATED TO METHOD OF ADMINISTRATION OF BPs: IV VS PO RELATED TO THE DURATION OF ADMINISTRATION VERY SERIOUS SEQUELAE WHEN ONJ DEVELOPS,BPs Mechanism of action,1) Tissue

    18、 levela. reduction of bone turnover2) Cellular levela. inhibition of osteoclastic activity on thebone surface (Rodan et al., Strewler)b. inhibition of osteoclast recruitment on thebone surface (Rodan et al., Vitte et al.)c. osteoclast apoptosis (Hughes et al., Rogers et al.),BPs Mechanism of action,

    19、3) Molecular levelInterferes with osteoclast intercellular biochemical pathways Inhibition of farnesyl diphosphate synthase Metabolized to toxic analogue of ATP (non-nitrogen containing BPs),Strewler GJ. N Engl J Med 2004;350:1174,Bisphosphonates,Pharmacologic action:- Inhibition of bone resorption

    20、Pharmacokinetics:- Distribution: Rapid accumulation in sites of increased bone deposition/resorption, low plasma levels, life of “years”- Metabolism: Not metabolized (nitrogen containing)- Excretion: Renal,Staging,Stage 1 Characterized by exposed bone that is asymptomatic with no evidence of signifi

    21、cant soft tissue infection,Staging,Stage 2Exposed bone associated with pain, soft tissue and/or bone infection,Staging,Stage 3 Pathologic fracture Exposed bone associated with soft tissue infection or pain that is not manageable with antibiotics due to the large volume of necrotic bone.,Staging,Stag

    22、e 3 Pathologic fracture Exposed bone associated with soft tissue infection or pain that is not manageable with antibiotics due to the large volume of necrotic bone.,A 40 yo with female with a diagnosis of breast cancer and Zometa therapy (6 months) presents with pain, exposed and infected maxillary

    23、bone following extraction,Relative Potency,Etidronate (Didronel) 1 Tiludronate (Skelide) 10 Pamidronate (Aredia) 100 Alendronate (Fosamax) 1,000 Risedronate (Actonel) 10,000 Ibandronate (Boniva) 10,000 Zolendronic acid (Zometa) 100,000,PROPOSAL,NEW DIAGNOSTIC ICD-9CM CODE FOR THE ASEPTIC NECROSIS OF

    24、 BONE IN THE JAWS: NEW CODE: 733.45 JAW (MAXILLA AND MANDIBLE) AND APPROPRIATE NEW E CODES TO IDENTIFY THE SPECIFIC ROUTE OF ADMINISTRATION E933.6 ORAL BISPHOSPHONATES AND E933.7 INTRAVENOUS BISPHOSPHONATES,Combinations,Use E933.1 antineoplastic & immunosuppressive drugs and May also need to Code for the primary neoplasm (most common ones are prostate, breast and myeloma),


    注意事项

    本文(BISPHOSPHONATE RELATEDOSTEONECROSIS OF THE .ppt)为本站会员(ideacase155)主动上传,麦多课文档分享仅提供信息存储空间,仅对用户上传内容的表现方式做保护处理,对上载内容本身不做任何修改或编辑。 若此文所含内容侵犯了您的版权或隐私,请立即通知麦多课文档分享(点击联系客服),我们立即给予删除!




    关于我们 - 网站声明 - 网站地图 - 资源地图 - 友情链接 - 网站客服 - 联系我们

    copyright@ 2008-2019 麦多课文库(www.mydoc123.com)网站版权所有
    备案/许可证编号:苏ICP备17064731号-1 

    收起
    展开